RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
RNAimmune has raised $27.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
RNAimmune's investors include Sirnaomics, Terra Magnum Capital Partners, Rotating Boulder Fund, Smooth River.
RNAimmune is headquartered in Gaithersburg, United States.
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
RNAimmune is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RNAimmune — Funding & Investors." VCBacked, March 29, 2022, https://www.vcbacked.co/company/rnaimmune. Accessed August 16, 2026.
VCBacked. (2022). RNAimmune — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/rnaimmune
{{cite web |title=RNAimmune — Funding & Investors |url=https://www.vcbacked.co/company/rnaimmune |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated